Remikiren (BioDeep_00000006505)

 

Secondary id: BioDeep_00001868560

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


(2S)-2-{[(2R)-2-benzyl-1-hydroxy-3-(2-methylpropane-2-sulphonyl)propylidene]amino}-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-5-yl)propanimidic acid

化学式: C33H50N4O6S (630.3451)
中文名称: 瑞米吉仑
谱图信息: 最多检出来源 Homo sapiens(blood) 77.31%

分子结构信息

SMILES: CC(C)(C)S(=O)(=O)CC(CC1=CC=CC=C1)C(=O)NC(CC2=CN=CN2)C(=O)NC(CC3CCCCC3)C(C(C4CC4)O)O
InChI: InChI=1S/C33H50N4O6S/c1-33(2,3)44(42,43)20-25(16-22-10-6-4-7-11-22)31(40)37-28(18-26-19-34-21-35-26)32(41)36-27(17-23-12-8-5-9-13-23)30(39)29(38)24-14-15-24/h4,6-7,10-11,19,21,23-25,27-30,38-39H,5,8-9,12-18,20H2,1-3H3,(H,34,35)(H,36,41)(H,37,40)/t25-,27+,28+,29+,30-/m1/s1

描述信息

Remikiren is only found in individuals that have used or taken this drug. It is an orally active, high specificity renin inhibitor. Several in vivo experiments have shown that remikiren is specific for renin and does not decrease arterial pressure by an unrelated mechanism.
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09X - Other agents acting on the renin-angiotensin system > C09XA - Renin-inhibitors
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

同义名列表

9 个代谢物同义名

(2S)-2-{[(2R)-2-benzyl-1-hydroxy-3-(2-methylpropane-2-sulphonyl)propylidene]amino}-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-5-yl)propanimidic acid; (2S)-2-{[(2R)-2-benzyl-1-hydroxy-3-(2-methylpropane-2-sulphonyl)propylidene]amino}-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-5-yl)propanimidate; (2S)-2-{[(2R)-2-benzyl-1-hydroxy-3-(2-methylpropane-2-sulfonyl)propylidene]amino}-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-5-yl)propanimidate; (2S)-2-[(2R)-2-benzyl-3-(2-methylpropane-2-sulfonyl)propanamido]-N-[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]-3-(1H-imidazol-5-yl)propanamide; (S)-alpha-((S)-alpha-((t-Butylsulfonyl)methyl)hydrocinnamamido)-N-((1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)imidazole-4-propionamide; Ro 42-5892; Ro 42-5892/001; Ro 42-5892; Remikiren; Remikiren



数据库引用编号

19 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 5 ACE, ACE2, ALB, EDN1, TXNRD3
Endosome membrane 1 CTSD
Endoplasmic reticulum membrane 1 SLC33A1
Nucleus 2 ALB, TXNRD3
cytosol 2 ALB, TXNRD3
centrosome 1 ALB
nucleoplasm 1 TXNRD3
Cell membrane 3 ACE, ACE2, AGTR2
Multi-pass membrane protein 3 AGTR2, CACNA1I, SLC33A1
Synapse 1 TAC1
cell surface 1 ACE2
Golgi apparatus 1 ALB
Golgi membrane 1 SLC33A1
lysosomal membrane 1 CTSD
neuronal cell body 1 TAC1
Lysosome 2 ACE, CTSD
endosome 2 ACE, CTSE
plasma membrane 9 ACE, ACE2, AGTR2, CACNA1I, EDNRA, INSRR, KNG1, REN, SLC33A1
Membrane 6 ACE, ACE2, CACNA1I, INSRR, REN, SLC33A1
apical plasma membrane 1 ACE2
axon 2 INSRR, TAC1
extracellular exosome 6 ACE, ACE2, AGT, ALB, CTSD, KNG1
endoplasmic reticulum 2 ALB, TXNRD3
extracellular space 9 ACE, ACE2, AGT, ALB, CTSD, EDN1, KNG1, REN, TAC1
lysosomal lumen 1 CTSD
mitochondrion 1 TXNRD3
protein-containing complex 1 ALB
intracellular membrane-bounded organelle 1 CTSE
Single-pass type I membrane protein 3 ACE, ACE2, INSRR
Secreted 6 ACE, ACE2, AGT, ALB, EDN1, REN
extracellular region 9 ACE, ACE2, AGT, ALB, CTSD, EDN1, KNG1, REN, TAC1
basal part of cell 1 EDN1
anchoring junction 1 ALB
Cell projection, cilium 1 ACE2
external side of plasma membrane 1 ACE
apical part of cell 1 REN
Apical cell membrane 1 ACE2
Membrane raft 2 ACE2, CTSD
collagen-containing extracellular matrix 3 AGT, CTSD, KNG1
receptor complex 1 INSRR
ciliary basal body 1 ALB
cilium 1 ACE2
centriole 1 ALB
Secreted, extracellular space 1 KNG1
brush border membrane 2 ACE, ACE2
spindle pole 1 ALB
blood microparticle 3 AGT, ALB, KNG1
sperm midpiece 1 ACE
endosome lumen 1 CTSD
Melanosome 1 CTSD
basal plasma membrane 1 ACE
Microsome 1 TXNRD3
ficolin-1-rich granule lumen 1 CTSD
endoplasmic reticulum lumen 3 ACE2, ALB, KNG1
platelet alpha granule lumen 2 ALB, KNG1
voltage-gated calcium channel complex 1 CACNA1I
specific granule lumen 1 CTSD
tertiary granule lumen 1 CTSD
endocytic vesicle membrane 1 ACE2
transport vesicle 1 EDN1
rough endoplasmic reticulum lumen 1 EDN1
Weibel-Palade body 1 EDN1
insulin receptor complex 1 INSRR
[Angiotensin-converting enzyme, soluble form]: Secreted 1 ACE
[Isoform Testis-specific]: Cell membrane 1 ACE
ciliary transition fiber 1 ALB
[Processed angiotensin-converting enzyme 2]: Secreted 1 ACE2
[Isoform 2]: Apical cell membrane 1 ACE2


文献列表

  • Rana H Refaey, Mohamed K El-Ashrey, Yassin M Nissan. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study. Virology. 2021 02; 554(?):48-54. doi: 10.1016/j.virol.2020.12.008. [PMID: 33370597]
  • Thomas Gossas, Lotta Vrang, Ian Henderson, Susanne Sedig, Christer Sahlberg, Erik Lindström, U Helena Danielson. Aliskiren displays long-lasting interactions with human renin. Naunyn-Schmiedeberg's archives of pharmacology. 2012 Feb; 385(2):219-24. doi: 10.1007/s00210-011-0718-7. [PMID: 22193701]
  • M Jadhav, C Yeola, G Zope, A Nabar. Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development. Journal of postgraduate medicine. 2012 Jan; 58(1):32-8. doi: 10.4103/0022-3859.93250. [PMID: 22387646]
  • Sundarapandian Thangapandian, Shalini John, Sugunadevi Sakkiah, Keun Woo Lee. Potential virtual lead identification in the discovery of renin inhibitors: application of ligand and structure-based pharmacophore modeling approaches. European journal of medicinal chemistry. 2011 Jun; 46(6):2469-76. doi: 10.1016/j.ejmech.2011.03.035. [PMID: 21497958]
  • Hernán Trimarchi. Role of aliskiren in blood pressure control and renoprotection. International journal of nephrology and renovascular disease. 2011; 4(?):41-8. doi: 10.2147/ijnrd.s6653. [PMID: 21694948]
  • Eduardo Pimenta, Suzanne Oparil. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Vascular health and risk management. 2009; 5(1):453-63. doi: 10.2147/vhrm.s4291. [PMID: 19475781]
  • Maarten Adh Schalekamp, Frans Hm Derkx, Jaap Deinum, Ah Jan Danser. Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. Journal of hypertension. 2008 May; 26(5):928-37. doi: 10.1097/hjh.0b013e3282f6a671. [PMID: 18398335]
  • Paolo Verdecchia, Fabio Angeli, Giovanni Mazzotta, Giorgio Gentile, Gianpaolo Reboldi. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vascular health and risk management. 2008; 4(5):971-81. doi: 10.2147/vhrm.s3215. [PMID: 19183745]
  • Max C Liebau, D Lang, J Böhm, N Endlich, Martin J Bek, Ian Witherden, Peter W Mathieson, Moin A Saleem, Hermann Pavenstädt, Karl-Georg Fischer. Functional expression of the renin-angiotensin system in human podocytes. American journal of physiology. Renal physiology. 2006 Mar; 290(3):F710-9. doi: 10.1152/ajprenal.00475.2004. [PMID: 16189286]
  • Pieter VAN Paassen, Dick DE Zeeuw, Paul E DE Jong, Gerjan Navis. Renin inhibition improves pressure natriuresis in essential hypertension. Journal of the American Society of Nephrology : JASN. 2000 Oct; 11(10):1813-1818. doi: 10.1681/asn.v11101813. [PMID: 11004211]
  • P van Paassen, D de Zeeuw, G Navis, P E de Jong. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2000 May; 15(5):637-43. doi: 10.1093/ndt/15.5.637. [PMID: 10809804]
  • P van Paassen, G J Navis, P E De Jong, D De Zeeuw. Pretreatment renal vascular tone predicts the effect of specific renin inhibition on natriuresis in essential hypertension. European journal of clinical investigation. 1999 Dec; 29(12):1019-26. doi: 10.1046/j.1365-2362.1999.00573.x. [PMID: 10583449]
  • J Bohlender, J Ménard, F C Luft, D Ganten. Dose effects of human renin in rats transgenic for human angiotensinogen. Hypertension (Dallas, Tex. : 1979). 1997 Apr; 29(4):1031-8. doi: 10.1161/01.hyp.29.4.1031. [PMID: 9095095]
  • H Buter, M H Hemmelder, P van Paassen, G Navis, D de Zeeuw, P E de Jong. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1997; 12 Suppl 2(?):53-6. doi: . [PMID: 9269701]
  • F H Derkx, R J de Bruin, J M van Gool, M J van den Hoek, C C Beerendonk, F Rosmalen, P Haima, M A Schalekamp. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clinical chemistry. 1996 Jul; 42(7):1051-63. doi: . [PMID: 8674188]
  • A Himmelmann, A Bergbrant, A Svensson, L Hansson, M Aurell. Remikiren (Ro 42-5892)--an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. American journal of hypertension. 1996 Jun; 9(6):517-22. doi: 10.1016/0895-7061(95)00340-1. [PMID: 8783774]
  • P Coassolo, W Fischli, J P Clozel, R C Chou. Pharmacokinetics of remikiren, a potent orally active inhibitor of human renin, in rat, dog and primates. Xenobiotica; the fate of foreign compounds in biological systems. 1996 Mar; 26(3):333-45. doi: 10.3109/00498259609046712. [PMID: 8730924]
  • J P van Kats, L M Sassen, A H Danser, M P Polak, L K Soei, F H Derkx, M A Schalekamp, P D Verdouw. Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren. British journal of pharmacology. 1996 Mar; 117(5):891-901. doi: 10.1111/j.1476-5381.1996.tb15277.x. [PMID: 8851507]
  • W F Richter, B R Whitby, R C Chou. Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals. Xenobiotica; the fate of foreign compounds in biological systems. 1996 Mar; 26(3):243-54. doi: 10.3109/00498259609046705. [PMID: 8730917]
  • R Jauch, P Schmid, W Fischli, W Meister, R Maurer, G Wendt. Excretion and metabolism of remikiren, a potent orally active inhibitor of primate renin. Xenobiotica; the fate of foreign compounds in biological systems. 1996 Mar; 26(3):285-95. doi: 10.3109/00498259609046708. [PMID: 8730920]
  • P van Paassen, D de Zeeuw, G Navis, P E de Jong. Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension?. Hypertension (Dallas, Tex. : 1979). 1996 Feb; 27(2):202-8. doi: 10.1161/01.hyp.27.2.202. [PMID: 8567042]
  • P van Paassen, D de Zeeuw, P E de Jong. Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension. Journal of cardiovascular pharmacology. 1995 Jul; 26(1):39-45. doi: 10.1097/00005344-199507000-00007. [PMID: 7564363]
  • G A Rongen, J W Lenders, P Smits, T Thien. Clinical pharmacokinetics and efficacy of renin inhibitors. Clinical pharmacokinetics. 1995 Jul; 29(1):6-14. doi: 10.2165/00003088-199529010-00002. [PMID: 7586899]
  • J Leube, G Fischer. Determination of the renin inhibitor Ro 42-5892 in human plasma by automated pre-column derivatization, reversed-phase high-performance liquid chromatographic separation and electrochemical detection after post-column irradiation. Journal of chromatography. B, Biomedical applications. 1995 Mar; 665(2):373-81. doi: 10.1016/0378-4347(94)00542-d. [PMID: 7795817]
  • R J MacFadyen, C R Jones, J K Doig, H Birnbock, J L Reid. Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans. Journal of cardiovascular pharmacology. 1995 Mar; 25(3):347-53. doi: 10.1097/00005344-199503000-00001. [PMID: 7769797]
  • W Kiowski, J Beermann, P Rickenbacher, R Haemmerli, M Thomas, F Burkart, T Meinertz. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation. 1994 Dec; 90(6):2748-56. doi: 10.1161/01.cir.90.6.2748. [PMID: 7994817]
  • M Azizi, T T Guyene, G Chatellier, J Ménard. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension. Journal of hypertension. 1994 Apr; 12(4):419-27. doi: . [PMID: 8064166]
  • C Weber, H Birnböck, J Leube, I Kobrin, C H Kleinbloesem, P Van Brummelen. Multiple dose pharmacokinetics and concentration effect relationship of the orally active renin inhibitor remikiren (Ro 42-5892) in hypertensive patients. British journal of clinical pharmacology. 1993 Dec; 36(6):547-54. doi: 10.1111/j.1365-2125.1993.tb00413.x. [PMID: 12959271]
  • F H Derkx, R J de Bruin, J M van Gool, F M Rosmalen, M J van Hoek, C C Beerendonk, M A Schalekamp. A novel assay of plasma prorenin using a renin inhibitor. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1993 Dec; 11(5):S240-1. doi: 10.1097/00004872-199312050-00099. [PMID: 8158364]
  • A H van den Meiracker, P J Admiraal, F H Derkx, C Kleinbloesem, A J Man in 't Veld, P van Brummelen, P Mulder, M A Schalekamp. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. Journal of hypertension. 1993 Aug; 11(8):831-8. doi: 10.1097/00004872-199308000-00010. [PMID: 8228207]
  • A I el Amrani, J Menard, M F Gonzales, J B Michel. Effects of blocking the angiotensin II receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs. Journal of cardiovascular pharmacology. 1993 Aug; 22(2):231-9. doi: 10.1097/00005344-199308000-00010. [PMID: 7692163]
  • J P Clozel, W Fischli. Comparative effects of three different potent renin inhibitors in primates. Hypertension (Dallas, Tex. : 1979). 1993 Jul; 22(1):9-17. doi: 10.1161/01.hyp.22.1.9. [PMID: 8319997]
  • C H Kleinbloesem, C Weber, E Fahrner, M Dellenbach, H Welker, V Schröter, G G Belz. Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects. Clinical pharmacology and therapeutics. 1993 May; 53(5):585-92. doi: 10.1038/clpt.1993.74. [PMID: 8491068]
  • I Kobrin, R J Viskoper, A Laszt, J Bock, C Weber, V Charlon. Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. American journal of hypertension. 1993 May; 6(5 Pt 1):349-56. doi: 10.1093/ajh/6.5.349. [PMID: 8512659]
  • J P Clozel, W Fischli, J Ménard. Effects of the blockade of the renin-angiotensin system in cyclosporin-induced hypertension. Journal of hypertension. 1993 Jan; 11(1):75-81. doi: 10.1097/00004872-199301000-00011. [PMID: 8382242]
  • J K Doig, R J MacFadyen, P A Meredith, W Fischli, J L Reid. Neurohormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42-5892, in salt-replete men. Journal of cardiovascular pharmacology. 1992 Dec; 20(6):875-80. doi: 10.1097/00005344-199212000-00005. [PMID: 1282588]
  • F H Derkx, J Deinum, M Lipovski, M Verhaar, W Fischli, M A Schalekamp. Nonproteolytic 'activation' of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. The Journal of biological chemistry. 1992 Nov; 267(32):22837-42. doi: 10.1016/s0021-9258(18)50023-5. [PMID: 1429632]
  • D Ganten, J Wagner, K Zeh, M Bader, J B Michel, M Paul, F Zimmermann, P Ruf, U Hilgenfeldt, U Ganten. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proceedings of the National Academy of Sciences of the United States of America. 1992 Aug; 89(16):7806-10. doi: 10.1073/pnas.89.16.7806. [PMID: 1502199]
  • M Véniant, J P Clozel, P Hess, W Fischli. Effects of renin-angiotensin system blockade in guinea pigs. Hypertension (Dallas, Tex. : 1979). 1992 Mar; 19(3):255-62. doi: 10.1161/01.hyp.19.3.255. [PMID: 1532164]
  • W Kiowski, L Linder, C Kleinbloesem, P van Brummelen, F R Bühler. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation. 1992 Jan; 85(1):1-8. doi: 10.1161/01.cir.85.1.1. [PMID: 1728438]
  • B Ba, G Eckert, J Leube. Use of dabsylation, column switching and chiral separation for the determination of a renin inhibitor in rat, marmoset and human plasma. Journal of chromatography. 1991 Dec; 572(1-2):277-89. doi: 10.1016/0378-4347(91)80492-u. [PMID: 1818062]
  • R R Luther, H N Glassman, R S Boger. Renin inhibitors in hypertension. Clinical nephrology. 1991 Oct; 36(4):181-6. doi: . [PMID: 1959244]
  • E Camenzind, J Nussberger, L Juillerat, A Munafo, W Fischli, P Coassolo, P van Brummelen, C H Kleinbloesem, B Waeber, H R Brunner. Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans. Journal of cardiovascular pharmacology. 1991 Sep; 18(3):299-307. doi: 10.1097/00005344-199109000-00001. [PMID: 1720828]
  • J Ménard, T T Guyene, G Chatellier, C H Kleinbloesem, P Bernadet. Renin release regulation during acute renin inhibition in normal volunteers. Hypertension (Dallas, Tex. : 1979). 1991 Sep; 18(3):257-65. doi: 10.1161/01.hyp.18.3.257. [PMID: 1889841]
  • W Fischli, J P Clozel, K el Amrani, W Wostl, W Neidhart, H Stadler, Q Branca. Ro 42-5892 is a potent orally active renin inhibitor in primates. Hypertension (Dallas, Tex. : 1979). 1991 Jul; 18(1):22-31. doi: 10.1161/01.hyp.18.1.22. [PMID: 1830563]
  • A H van den Meiracker, P J Admiraal, A J Man in 't Veld, F H Derkx, H J Ritsema van Eck, P Mulder, P van Brummelen, M A Schalekamp. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension. BMJ (Clinical research ed.). 1990 Jul; 301(6745):205-10. doi: 10.1136/bmj.301.6745.205. [PMID: 2203486]